1. Market Research
  2. > Biotechnology Market Trends
  3. > Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015

The Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter licensing deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of licensing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part.

Chapter 4 provides a review of the leading licensing deals since 2011. Deals are listed by headline value, signed by bigpharma, most active big pharma, signed by big biotech, most active big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of licensing financials for deals announced since 2011, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of licensing deals signed and announced since 2011 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2011.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.

In addition, a comprehensive appendix is provided organized by licensing company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing partnering in the research, development and commercialization of technologies and products.

Report scope

Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.

Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 includes:

Trends in licensing dealmaking in the biopharma industry since 2011
Analysis of licensing deal structure
Case studies of real-life licensing deals
Comprehensive listing of licensing deals since 2011
Access to licensing contract documents
Key financial bnchmarks for headline, upfront, milestone and royalty rates
The leading licensing deals by value since 2011
Most active licensing dealmakers since 2011
The leading licensing partnering resources
In Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 available deals and contracts are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 provides the reader with the following key benefits:

In-depth understanding of licensing partnering deal trends since 2011
Insight into the terms included in a licensing agreement, together with real world clause examples
Identify leading licensing deals by value since 2011
Identify the most active licensing dealmakers since 2011
Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
Full listing of licensing deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
Comprehensive access to over 3,500 licensing deals entered into by the world’s biopharma companies, together with contract documents if available
Detailed access to actual licensing contracts entered into by the leading fifty big pharma and big biotech companies
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Licensing Terms and Agreements in Pharma, Biotech and Diagnostics 2011-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2011
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta - Nerviano Medical Sciences - November 2013
3.3.1.b. Case study 2: Sanofi - Pozen - September 2013
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics - UniQure - January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin - Ultragenyx Pharmaceuticals - September 2013
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories - Trevena - May 2013
3.4.2.b. Case study 6: Abbvie - Receptos - March 2013

Chapter 4 - Leading licensing deals

4.1. Introduction
4.2. Top licensing deals by value
4.3. Most active licensing dealmakers
4.3.1 Most active licensing dealmakers by therapy
4.3.2. Most active licensing dealmaker by stage of development
4.4. Big pharma licensing deal activity
4.4. Big biotech licensing deal activity

Chapter 5 - Licensing deal term benchmarks

5.1. Introduction
5.1.2. Licensing headline values
5.1.3. Licensing upfront payments
5.1.4. Licensing milestone payments
5.1.5. Licensing royalty rates

Chapter 6 - Big pharma licensing deals

6.1. Introduction
6.2. How to use licensing deals
6.3. Big pharma company licensing agreement listings

Chapter 7 - Big biotech licensing deals

7.1. Introduction
7.2. How to use licensing deals
7.3. Big biotech licensing agreement listings

Chapter 8 - Licensing contract directory 2011-2015

8.1. Introduction
8.2. Company A-Z
8.3. By therapy area
8.4. By stage of development at signing
8.5. By technology area

Appendix
Appendix 1 - Resources
Appendix 2 - Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

Additonal appendices - see separate PDF documents:
Appendix 1 - Licensing dealmaking - by financial disclosure
Appendix 2 - Licensing dealmaking - by companies A-Z
Appendix 3 - Licensing dealmaking - by stage of development
Appendix 4 - Licensing dealmaking - by therapeutic target
Appendix 5 - Licensing dealmaking - by technology type

TABLE OF FIGURES

Figure 1: Definition of licensing
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements, 2011-2015
Figure 5: Licensing deals signed at each phase of development, 2011-2015
Figure 6: Licensing deals by therapy area, 2011-2015
Figure 7: Licensing agreements - what should a contract include?
Figure 8: Components of the licensing deal structure
Figure 9: Top licensing deals by value since 2011 exceeding $1bn
Figure 10: Most active licensing dealmakers 2011-2015
Figure 11: Most active licensing dealmakers 2011-2015 by therapy area
Figure 12: Most active licensing dealmakers 2011-2015 - by stage of development
Figure 13: Big pharma - top 50 - licensing deals 2010 to 2015
Figure 14: Big pharma licensing deal frequency - 2010 to 2015
Figure 15: Big biotech - top 50 - licensing deals 2010 to 2015
Figure 16: Big biotech licensing deal frequency - 2009 to 2015
Figure 17: Licensing deals headline value distribution, US$million - discovery stage
Figure 18: Licensing deals headline value distribution, US$million - preclinical stage
Figure 19: Licensing deals headline value distribution, US$million - phase I stage
Figure 20: Licensing deals headline value distribution, US$million - phase II stage
Figure 21: Licensing deals headline value distribution, US$million - phase III stage
Figure 22: Licensing deals headline value distribution, US$million - regulatory stage
Figure 23: Licensing deals headline value distribution, US$million - marketed stage
Figure 24: Licensing deal upfront payment distribution, US$million - discovery stage
Figure 25: Licensing deal upfront payment distribution, US$million - preclinical stage
Figure 26: Licensing deals upfront value distribution, US$million - phase I stage
Figure 27: Licensing deals upfront value distribution, US$million - phase II stage
Figure 28: Licensing deals upfront value distribution, US$million - phase III stage
Figure 29: Licensing deals upfront value distribution, US$million - regulatory stage
Figure 30: Licensing deals upfront value distribution, US$million - marketed stage
Figure 31: Licensing deal milestone distribution, US$million - discovery stage
Figure 32: Licensing deals milestone distribution, US$million - preclinical stage
Figure 33: Licensing deals milestone distribution, US$million - phase I stage
Figure 34: Licensing deals milestone distribution, US$million - phase II stage
Figure 35: Licensing deals milestone distribution, US$million - phase III stage
Figure 36: Licensing deals milestone distribution, US$million - regulatory stage
Figure 37: Licensing deals milestone distribution, US$million - marketed stage
Figure 38: Licensing deals with royalty rates, %
Figure 39: Licensing deals royalty rate distribution, %- discovery stage
Figure 40: Licensing deals royalty rate distribution, %- preclinical stage
Figure 41: Licensing deals royalty rate distribution, %- phase I stage
Figure 42: Licensing deals royalty rate distribution, %- phase II stage
Figure 43: Licensing deals royalty rate distribution, %- phase III stage
Figure 44: Licensing deals royalty rate distribution, %- regulatory stage
Figure 45: Licensing deals royalty rate distribution, %- marketed stage
Figure 46: Online partnering resources
Figure 47: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

  • $ 18000
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global bioreactors market is expected to reach to USD 1,417 million by 2021 from USD 955 million in 2015, at a CAGR of 6.8% between 2015 and 2021.The increase in adoption of single-use technologies, ...

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.